| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(14)70017-8 |
| P698 | PubMed publication ID | 24988936 |
| P50 | author | Elio Castagnola | Q89619280 |
| Thomas Lehrnbecher | Q89752780 | ||
| Jean-Hugues Dalle | Q90590340 | ||
| Werner J. Heinz | Q42958840 | ||
| Emmanuel Roilides | Q61097982 | ||
| Andreas H Groll | Q87921006 | ||
| Jan Styczyński | Q89490548 | ||
| William Hope | Q37370273 | ||
| Simone Cesaro | Q40475424 | ||
| P2093 | author name string | Adilia Warris | |
| Dan Engelhard | |||
| European Leukaemia Net (ELN) | |||
| Fourth European Conference on Infections in Leukaemia | |||
| Infectious Diseases Group of the European Organisation for Research and Treatment of Cancer (EORTC-IDG) | |||
| Infectious Diseases Working Party of the European Group for Blood Marrow Transplantation (EBMT-IDWP) | |||
| International Immunocompromised Host Society (ICHS) | |||
| P2860 | cites work | β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3) | Q26825753 |
| Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial | Q28277029 | ||
| Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions | Q29399166 | ||
| Quantification of 1,3-beta-D-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting | Q31114184 | ||
| Use of amphotericin B colloidal dispersion in children | Q31397984 | ||
| Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data | Q33559503 | ||
| High Levels of beta-D-glucan in immunocompromised children with proven invasive fungal disease | Q33825648 | ||
| Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. | Q33830384 | ||
| Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. | Q34020746 | ||
| International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. | Q34151084 | ||
| Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study | Q34166590 | ||
| A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients | Q40645972 | ||
| ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. | Q43944046 | ||
| Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections | Q44417870 | ||
| Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens | Q44469244 | ||
| The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis | Q44718453 | ||
| The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial | Q44924916 | ||
| Combination antifungal therapy for invasive aspergillosis | Q45096994 | ||
| European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update | Q46050924 | ||
| Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay | Q46503389 | ||
| Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients | Q46779888 | ||
| Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders | Q46881537 | ||
| Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). | Q46946844 | ||
| Candidaemia in a European Paediatric University Hospital: a 10-year observational study. | Q50984327 | ||
| Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. | Q51617424 | ||
| Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. | Q52222221 | ||
| The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. | Q53465238 | ||
| Cerebral aspergillosis in an infant with corticosteroid-resistant nephrotic syndrome | Q53653072 | ||
| Primary antifungal prophylaxis in leukaemia patients | Q56611060 | ||
| Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients | Q56611061 | ||
| Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery | Q57220656 | ||
| Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis | Q61758327 | ||
| Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis | Q71644655 | ||
| CT of invasive pulmonary aspergillosis in children with cancer | Q72834120 | ||
| Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules | Q73460720 | ||
| Guide to development of practice guidelines | Q73613158 | ||
| Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients | Q80538847 | ||
| β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis | Q83514901 | ||
| Time for paediatric febrile neutropenia guidelines - children are not little adults | Q83523948 | ||
| Standardization of Aspergillus PCR diagnosis | Q83666904 | ||
| Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases | Q84839346 | ||
| Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation | Q34368144 | ||
| Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation | Q34450423 | ||
| Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients | Q35270270 | ||
| Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation | Q35659502 | ||
| Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients | Q35799730 | ||
| Development of a serum-based Taqman real-time PCR assay for diagnosis of invasive aspergillosis | Q36241681 | ||
| Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients | Q36593781 | ||
| Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). | Q36862446 | ||
| Zygomycosis in children: a systematic review and analysis of reported cases | Q36937857 | ||
| Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective | Q36948094 | ||
| Clinical pharmacology of antifungal agents in pediatric patients | Q36968140 | ||
| Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases | Q37152392 | ||
| Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ | Q37164067 | ||
| Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria | Q37164085 | ||
| Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis | Q37244986 | ||
| The First European Conference on Infections in Leukaemia - ECIL1: a current perspective | Q37245348 | ||
| Invasive fungal infections in children | Q37562755 | ||
| Zygomycetes infections in pediatric hematology oncology patients: a case series and review of the literature. | Q37621232 | ||
| Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma | Q37761047 | ||
| Diagnosis of invasive fungal infections in immunocompromised children | Q37777195 | ||
| Update on antifungal agents for paediatric patients | Q37777197 | ||
| Invasive aspergillosis in children with acquired immunodeficiencies | Q37954958 | ||
| Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice | Q37993110 | ||
| Evaluation of pan-fungal PCR assay and Aspergillus antigen detection in the diagnosis of invasive fungal infections in high risk paediatric cancer patients | Q38988515 | ||
| Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis | Q39697409 | ||
| Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. | Q39899742 | ||
| Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation | Q40274081 | ||
| A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children | Q40287559 | ||
| Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study | Q40331138 | ||
| A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. | Q40359965 | ||
| Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study | Q40376327 | ||
| Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. | Q40395042 | ||
| Computed tomography in the evaluation of febrile neutropenic pediatric oncology patients | Q40608893 | ||
| P433 | issue | 8 | |
| P921 | main subject | leukemia | Q29496 |
| patient | Q181600 | ||
| prevention | Q1717246 | ||
| stem cell transplantation | Q65592366 | ||
| P304 | page(s) | e327-40 | |
| P577 | publication date | 2014-07-01 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation | |
| P478 | volume | 15 |
| Q64120981 | A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia |
| Q39247468 | A review of infectious complications after haploidentical hematopoietic stem cell transplantations |
| Q57476185 | Advances in the Treatment of Mycoses in Pediatric Patients |
| Q49929057 | Advancing a field by building consortia: The example of the European LeukemiaNet |
| Q48202890 | Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations |
| Q91785476 | AlloHSCT in paediatric ALL and AML in complete remission: improvement over time impacted by accreditation? |
| Q38264086 | Anti-infective prophylaxis in pediatric patients with acute myeloid leukemia |
| Q28074168 | Antifungal Prophylaxis in Immunocompromised Patients |
| Q37280740 | Antifungal prophylaxis of patients undergoing allogenetic hematopoietic stem cell transplantation in China: a multicenter prospective observational study |
| Q40215709 | Azole-resistant Aspergillus fumigatus in sawmills of Eastern France. |
| Q38693242 | Biomarker-based diagnostic work-up of invasive pulmonary aspergillosis in immunocompromised paediatric patients--is Aspergillus PCR appropriate? |
| Q51608149 | Bronchoalveolar galactomannan in invasive pulmonary aspergillosis: a prospective study in pediatric patients. |
| Q36630796 | Candida Associated Bloodstream Infections in Pediatric Hematology Patients: A Single Center Experience |
| Q35905124 | Clinical Features and Prognosis of Invasive Pulmonary Aspergillosis in Korean Children with Hematologic/Oncologic Diseases |
| Q40063394 | Clinical considerations in the early treatment of invasive mould infections and disease. |
| Q38314467 | Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients |
| Q90048773 | Clinical practice update of antifungal prophylaxis in immunocompromised children |
| Q36053792 | Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia |
| Q40060170 | Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis |
| Q38284455 | Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. |
| Q38822532 | Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology. |
| Q40454880 | Current Algorithms in Fungal Diagnosis in the Immunocompromised Host. |
| Q38798744 | Current strategies against invasive fungal infections in patients with aplastic anemia, strong power and weak weapon, a case report and review of literature |
| Q93050011 | Definition of Opportunistic Infections in Immunocompromised Children on the Basis of Etiologies and Clinical Features: A Summary for Practical Purposes |
| Q40279616 | Detection of Polish clinical Aspergillus fumigatus isolates resistant to triazoles |
| Q39361503 | Development of indicators for evaluating the appropriate use of triazoles for invasive fungal disease: A Delphi panel survey |
| Q52720488 | Diagnostic Approaches for Invasive Aspergillosis-Specific Considerations in the Pediatric Population. |
| Q64079390 | Drug-drug interaction study of imatinib and voriconazole in vitro and in vivo |
| Q40309090 | Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. |
| Q41996461 | Epidemiology of Invasive Fungal Disease in Children |
| Q38827118 | Epidemiology of invasive fungal diseases in children with solid tumours undergoing autologous haematopoietic stem cell transplantation: a 10-year experience in a tertiary Italian centre |
| Q40039417 | Evaluation of a fever-management algorithm in a pediatric cancer center in a low-resource setting. |
| Q92619791 | Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment |
| Q59590907 | Fungal Infections in the Pediatric Age Group |
| Q47580986 | Fungal Prophylaxis with a Gastro-Resistant Posaconazole Tablet for Patients with Hematological Malignancies in the POSANANTES Study |
| Q90225865 | Fungal infections in children with haematologic malignancies and stem cell transplant recipients |
| Q90045405 | Galactomannan and PCR in the Central Nervous System to Detect Invasive Mold Disease - A Retrospective Analysis in Immunocompromised Children |
| Q30244009 | Galactomannan, β-D-Glucan, and Polymerase Chain Reaction-Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis |
| Q40994236 | Impact of a change in protected environment on the occurrence of severe bacterial and fungal infections in children undergoing hematopoietic stem cell transplantation |
| Q38462784 | Impact of special patient populations on the pharmacokinetics of echinocandins. |
| Q64108338 | Incidence and Outcome of Invasive Fungal Diseases in Children With Hematological Malignancies and/or Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Multicenter Study |
| Q51149049 | Infections Caused by Fusarium Species in Pediatric Cancer Patients and Review of Published Literature. |
| Q38388198 | Infectious complications in children with acute lymphoblastic leukemia treated in low-middle-income countries |
| Q36548058 | Infectious complications in children with acute myeloid leukemia: decreased mortality in multicenter trial AML-BFM 2004. |
| Q92861746 | Infectious complications in children with malignant bone tumors: a multicenter nationwide study |
| Q38690098 | Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT. |
| Q58775551 | Invasive Aspergillosis in Children: Update on Current Guidelines |
| Q64229013 | Invasive Aspergillosis in Pediatric Leukemia Patients: Prevention and Treatment |
| Q57457645 | Invasive Fungal Disease in Children with Acute Leukemia: The Elusive Culprit |
| Q92812155 | Invasive Fungal Disease, Isavuconazole Treatment Failure, and Death in Acute Myeloid Leukemia Patients |
| Q38263282 | Invasive candidiasis and candidaemia in neonates and children: update on current guidelines |
| Q92607485 | Invasive mucormycosis during treatment for acute lymphoblastic leukaemia-successful management of two life-threatening diseases |
| Q39704919 | Lack of Effectiveness of Neutropenic Diet and Social Restrictions as Anti-Infective Measures in Children With Acute Myeloid Leukemia: An Analysis of the AML-BFM 2004 Trial |
| Q38817878 | Lichtheimia Infection in a Lymphoma Patient: Case Report and a Brief Review of the Available Diagnostic Tools |
| Q39196802 | Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use. |
| Q92180354 | Micafungin as antifungal prophylaxis in non-transplanted haemotological patients |
| Q40790252 | Micafungin in invasive fungal infections in children with acute leukemia or undergoing stem cell transplantation. |
| Q41559852 | Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease |
| Q50113596 | Multi-locus sequence typing provides epidemiological insights for diseased sharks infected with fungi belonging to the Fusarium solani species complex |
| Q41444763 | Need of voriconazole high dosages, with documented cerebrospinal fluid penetration, for treatment of cerebral aspergillosis in a 6-month-old leukaemic girl |
| Q59358378 | Neurological complications of hematopoietic cell transplantation in children and adults |
| Q40273481 | New pharmacological opportunities for the treatment of invasive mould diseases. |
| Q40204491 | Nosocomial legionellosis and invasive aspergillosis in a child with T-lymphoblastic leukemia |
| Q91705002 | Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee |
| Q38391049 | Our 2015 approach to invasive pulmonary aspergillosis. |
| Q49612998 | Pediatric Invasive Aspergillosis |
| Q38611989 | Performance of 1,3-β-D-glucan for diagnosing invasive fungal diseases in children |
| Q36730105 | Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy |
| Q47781187 | Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children. |
| Q38816614 | Pharmacokinetic considerations in treating invasive pediatric fungal infections |
| Q48118247 | Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients |
| Q92782666 | Pre-emptive versus empirical antifungal therapy in immunocompromised children |
| Q36353240 | Prevalence of the reversed halo sign in neutropenic patients compared with non-neutropenic patients: Data from a single-centre study involving 27 patients with pulmonary mucormycosis (2003-2016). |
| Q26782472 | Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole |
| Q36406975 | Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. |
| Q36792818 | Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation |
| Q39416559 | Progress in the Diagnosis of Invasive Fungal Disease in Children. |
| Q37581839 | Prospective Biomarker Screening for Diagnosis of Invasive Aspergillosis in High-Risk Pediatric Patients. |
| Q41929675 | Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children. |
| Q57137945 | Repeated antifungal use audits are essential for selecting the targets for intervention in antifungal stewardship |
| Q40968242 | Resistant fungi |
| Q40194039 | Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric onco-hematological patients. |
| Q41996456 | Role of Molecular Biomarkers in the Diagnosis of Invasive Fungal Diseases in Children |
| Q39036999 | Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation-a retrospective national multicenter study |
| Q35689788 | Serum galactomannan index for early prediction of mortality in immunocompromised children with invasive pulmonary aspergillosis |
| Q51697464 | Sinus aspergillosis due to an azole-resistant Aspergillus fumigatus strain carrying the TR34/L98H mutation in immunocompetent host. |
| Q30244244 | Strategies for reducing the treatment-related physical burden of childhood acute myeloid leukaemia - a review |
| Q41989698 | Successful Treatment of Invasive Conidiobolus Infection During Therapy for Acute Lymphoblastic Leukemia |
| Q40961845 | Successful haploidentical stem cell transplantation with prophylactic administration of liposomal amphotericin B after invasive pulmonary zygomycosis. |
| Q59790970 | Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report |
| Q55313368 | Synergistic and antagonistic effects of immunomodulatory drugs on the action of antifungals against Candida glabrata and Saccharomyces cerevisiae. |
| Q35105787 | Systemic antifungal prescribing in neonates and children: outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) Study |
| Q46516037 | TACL'ing supportive care needs in pediatric early phase clinical trials for acute leukemia: A report from the therapeutic advances in childhood leukemia & lymphoma (TACL) consortium supportive care committee |
| Q26749001 | The European Paediatric Mycology Network (EPMyN): Towards a Better Understanding and Management of Fungal Infections in Children |
| Q39002810 | The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood. |
| Q40438373 | The role of the multidisciplinary team in antifungal stewardship. |
| Q42101900 | Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment. |
| Q38709104 | Therapeutic drug monitoring in neonates |
| Q38353420 | Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients: an update |
| Q47566809 | Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia |
| Q90051374 | Updates in Laboratory Diagnostics for Invasive Fungal Infections |
| Q50072321 | Use of 1,3-β-D-glucan in invasive fungal diseases in hematology patients |
| Q38965488 | Use of Fungal Diagnostics and Therapy in Pediatric Cancer Patients in Resource-Limited Settings |
| Q54243380 | Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis. |
| Q57268678 | Variability in Antifungal and Antiviral Use in Hospitalized Children |
| Q39893350 | Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre |
| Q42377772 | Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia |
| Q35868758 | β-D-Glucan Screening for Detection of Invasive Fungal Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation |
Search more.